New drug combo shows promise for rare thymic cancer
NCT ID NCT03463460
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This study tested a combination of two drugs, pembrolizumab and sunitinib, in 9 people with advanced thymic cancer that had spread or could not be removed and had stopped responding to standard chemotherapy. The goal was to see if the combination could shrink tumors or stop them from growing. The approach uses the immune system and blocks cancer cell growth signals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYMIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Indiana University
Indianapolis, Indiana, 46202, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Shorter radiation after thymic tumor surgery may cut side effects
- Fewer radiation sessions may be just as effective for thymic tumors after surgery
- Immune cells engineered to hunt thymus cancer show promise in early trial
- Immunotherapy drug nivolumab tested for rare thymus cancers
- New combo therapy shows promise for rare chest cancer
- New trial aims to stop thymic cancer return with Chemo-Radiation combo